Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) (NCT05714085)
A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction (VALOR)
🩺 Plain-English Summary (8th-Grade Level)
This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.
Who can join: Review the eligibility criteria below.
Location: The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 0002) — Los Angeles, California
Age range: 29 Days to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (109 Sites)
Showing the first 25 of 109 sites.
- The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 0002) — Los Angeles, California
- Lucile Packard Children's Hospital ( Site 0040) — Palo Alto, California
- Loma Linda University Health System ( Site 0008) — San Bernardino, California
- Children's Hospital Colorado ( Site 0012) — Aurora, Colorado
- Children's National Medical Center ( Site 0020) — Washington D.C., District of Columbia
- Johns Hopkins All Children's Hospital ( Site 0029) — St. Petersburg, Florida
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital ( Site 0001) — Atlanta, Georgia
- Boston Children's Hospital ( Site 0035) — Boston, Massachusetts
- C.S. Mott Children's Hospital ( Site 0033) — Ann Arbor, Michigan
- Washington University-Pediatric Cardiology/ St. Louis Children's Hospital ( Site 0006) — St Louis, Missouri
- Columbia University Medical Center-Pediatric Cardiology ( Site 0016) — New York, New York
- The Children's Hospital at Montefiore ( Site 0030) — The Bronx, New York
- Cincinnati Children's Hospital Medical Center ( Site 0034) — Cincinnati, Ohio
- Cleveland Clinic-Cleveland Clinic Chidren's ( Site 0022) — Cleveland, Ohio
- Children's Hospital of Philadelphia (CHOP) ( Site 0004) — Philadelphia, Pennsylvania
- Children's Hospital of Pittsburgh ( Site 0010) — Pittsburgh, Pennsylvania
- Le Bonheur Children's Hospital ( Site 0007) — Memphis, Tennessee
- Children's Health-The Heart Center ( Site 0015) — Dallas, Texas
- Texas Children's Hospital ( Site 0039) — Houston, Texas
- Seattle Children's Hospital-Cardiology/Fetal Therapy ( Site 0019) — Seattle, Washington
- Centre Hospitalier Régional de la Citadelle ( Site 0302) — Liège, Liege
- UZ Gent ( Site 0301) — Ghent, Oost-Vlaanderen
- UZ Leuven ( Site 0300) — Leuven, Vlaams-Brabant
- Instituto Dante Pazzanese de Cardiology ( Site 0402) — São Paulo, São Paulo
- Incor - Instituto do Coracao ( Site 0400) — São Paulo,
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Heart Failure
- REDUCE LAP-HFREF TRIAL — New York, New York
- Physiological Effects Ketone Ester in Heart — Cleveland, Ohio
- DASH Diet in Heart Failure Outpatients — Sacramento, California
- Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients — Huntsville, Alabama
- LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System. — Birmingham, Alabama
- A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation — Alexander City, Alabama
Explore by condition: All Heart Failure clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.